8:45 am
Registration & Virtual Morning Coffee Networking
9:00 am Chair’s Opening Remarks
Advances in Preclinical Oncology Model Utilization
9:10 am Organoids: A Revolutionary New Tool for Drug Screening
Synopsis
• Discover organoids as a more physiologically relevant 3D in vitro model
• Find out why HUB organoids are considered a best-in-class system
• Understand how organoids are revolutionizing oncology drug development
• Learn how patient-derived xenografts (PDX) can be leveraged to develop the largest organoid library for oncology drug discovery
9:40 am Leveraging Preclinical Mouse Models to Understand Cancer Cell Behavior at Secondary Sites & Quantify the Risk of Tumor Metastasis
Synopsis
• Understanding the nature of cancer heterogeneity and how this necessitates personalized therapies
• Conducting predictive analysis to determine tumor aggression and metastatic spread likelihood
• Utilizing multiple syngeneic mouse models to trace the fate of metastatic cells from the primary site to distant organs
10:00 am The Use of Humanized Mice for the Preclinical Evaluation of Bispecific Antibody Efficacy & Safety for Immune-Oncology Research
Synopsis
• The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization
• Showcase data on the myeloid engraftment kinetics and show checkpoint inhibitor efficacy against several PDX
10:30 am Live Q&A – Ask the Panel Your Burning Questions
11:15 am
Virtual Speed Networking
Synopsis
Recreating the face-to-face networking in the virtual world. We will pair you up with
fellow attendees to break the ice and make new business relationships!
11:50 am
Morning Break
• Live Demo in Virtual Exhibition Hall
• One-to-One Meetings
Dedicated Roundtable Discussion Chatroom:
• Using Patient Tissue Sample as an Effective Tool to
• Overcome Resistance and Translation Challenges
Preclinical Models for Drug Discovery From Drug Discovery to Target Validation
12.00 Identifying Predictive & Prognostic Biomarkers Through Preclinical Modeling of Syngeneic Tumors
Maryland Franklin, Executive Director, Scientific Development, Covance
12.30 Combination of a novel RAF/MEK inhibitor, CH5126766, with the FAK inhibitor defactinib for the treatment of KRAS mutant cancer
Silvia Coma, Associate Director, Verastem Oncology
12.50 Live Q&A - Ask Speakers Your Burning Questions
Preclinical Models for Drug Development From Tox to Safety Profiling
12.00 Development of Brain Metastasis Cancer Models from Heavily Treated Patients & Strategies
Kin-Hoe Chow, Associate Director of Center for Patient Derived Models, Dana Farber Cancer Institute
12.20 Overcoming Translational Barriers by using the SRG Rat: Case Studies with the OncoRat®
Fallon Noto, Director In Vivo & Oncology Services, Hera BioLabs
12.50 Live Q&A - Ask Speakers Your Burning Questions
1:15 pm Networking Lunch
• Live Demo in Virtual Exhibition Hall
• One-to-One Meetings
Dedicated Roundtable Discussion Chatroom:
• Understanding Metastatic Spread Throughout Different
Organs by Studying Patient Samples
Preclinical Models for Drug Discovery From Drug Discovery to Target Validation
2.00 In Vivo Efficacy & Toxicity Evaluation Using Various Humanized Mouse Models to Increase Clinical Translation
Qingcong Lin, CEO, Biocytogen Boston Corporation
2.20 Assessment of Murine Colorectal Cancer by UHF Ultrasound Using 3D Reconstruction & Nonlinear Contrast Imaging
Jessica Freeling, Physiology Core Facility Director, The University of South Dakota
2.40 Live Q&A - Ask Speakers Your Burning Questions
Preclinical Models for Drug Development From Tox to Safety Profiling
2.00 SubQperior: A Superior Syngeneic Model System to Subcutaneous Tumor Models
Holger Weber, Head of In Vivo, Pharmacology, ProQinase
2.30 Adopting the Appropriate Model for Your Target Therapy
Sangeetha Palakurthi, Vice President, Elstar Therapeutic
2.50 Live Q&A - Ask Speakers Your Burning Questions
3:15 pm Afternoon Break & Poster Session
Harnessing Tumor Models to Overcome Low Translation Outside the Clinic
4:00 pm Assessment of Biologics’ Efficacy Using Preclinical Models Featuring Humanized Immune Checkpoint Models or Stem Cell-Reconstituted Immunodeficient Mice
Synopsis
• Understanding the breakthrough of immunotherapy for the success of cancer therapy
• Exploring why there are subsets of patients, which do not show robust response to immunotherapy
• Navigating the limitations of immuno-oncology to ensure preclinical models recapitulate the complexity of the etiology of tumors
• Exploring how immune checkpoint models as well humanized as immunodeficient mice can be harnessed to interrogate and model anti-tumor immune response
4:30 pm Multidisciplinary Science Elucidates Drug Resistance in Cancer: Integration of Mathematics & Tumor Models
Synopsis
• Methods to integrate the entirety of the tumor ecosystem to interrogate drug resistance
• Blending ex vivo and in vivo models with computational biology to understand how anti-cancer drugs drive tumor resistance
• Utilizing stochastic, deterministic, systems biology and game theory models to uncover novel biological behavior
• Validating mechanistic biology and confirming efficacy of novel drug combinations, in vivo
4:50 pm Live Q&A – Ask Our Speakers Your Burning Questions
5:20 pm Chair’s Closing Remarks
5:45 pm
Virtual Drinks Reception & Roundtable hosted by Crown Bioscience
Synopsis
Join Crown Bioscience’s virtual drinks reception and poster session to help you connect with your peers in a relaxed atmosphere. Continue scientific discussions following the day 1’s presentations and forge new relationships with your fellows.